Targeted therapy including BRAF and MEK inhibitors and immune checkpoint inhibitors are the standard of care for unresectable locally advanced and metastatic melanomas with BRAFV600E/K mutations. This evidence concerns the gene MAP2K7 and metastatic melanoma.